May 30, 2014
Bayer Yakuhin filed its oral anticoagulant Xarelto (rivaroxaban) for the treatment of venous thromboembolism (VTE) and prevention of recurrent VTE as an additional indication on May 28, the company said the same day. VTE is a general term used to...read more